Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Strides Pharma Science Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 986 | 930 | 999 | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 |
| Expenses + | 871 | 796 | 889 | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 |
| Operating Profit | 115 | 134 | 111 | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 |
| OPM % | 12% | 14% | 11% | 13% | 16% | 18% | 16% | 18% | 18% | 19% | 19% | 20% | 18% |
| Other Income + | 20 | 3 | -129 | 60 | -27 | 3,299 | 25 | 4 | -12 | 0 | 18 | 104 | 3 |
| Interest | 81 | 76 | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 |
| Depreciation | 61 | 60 | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 |
| Profit before tax | -7 | 0 | -157 | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 |
| Tax % | 106% | 3,025% | -5% | 23% | 55% | 1% | 16% | 21% | 20% | 13% | 14% | 15% | 13% |
| Net Profit + | -14 | -9 | -149 | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 |
| EPS in Rs | -1.06 | -0.79 | -14.54 | 5.40 | 1.98 | 364.69 | 7.81 | 9.54 | 8.91 | 10.80 | 13.84 | 21.93 | 13.77 |
Financials of Strides Pharma Science Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,196 | 2,861 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 |
| Expenses + | 967 | 2,486 | 2,228 | 2,448 | 1,982 | 2,338 | 2,779 | 3,201 | 3,544 | 3,362 | 3,763 | 3,933 |
| Operating Profit | 229 | 374 | 527 | 398 | 197 | 414 | 537 | -131 | 145 | 528 | 803 | 925 |
| OPM % | 19% | 13% | 19% | 14% | 9% | 15% | 16% | -4% | 4% | 14% | 18% | 19% |
| Other Income + | 874 | 63 | 291 | 643 | 303 | -43 | 109 | -112 | 92 | -100 | 3,313 | 124 |
| Interest | 47 | 168 | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 280 | 249 | 179 |
| Depreciation | 64 | 131 | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 214 | 192 | 202 |
| Profit before tax | 992 | 137 | 509 | 690 | 303 | 42 | 289 | -653 | -268 | -65 | 3,675 | 669 |
| Tax % | 15% | 31% | 12% | 1% | -9% | 27% | 11% | -27% | -21% | 45% | 2% | 14% |
| Net Profit + | 844 | 95 | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 3,598 | 575 |
| EPS in Rs | 141.78 | 12.15 | 44.71 | 74.25 | 36.27 | 4.06 | 29.93 | -51.25 | -22.44 | -7.68 | 389.75 | 60.34 |
| Dividend Payout % | 76% | 41% | 10% | 3% | 8% | 345% | 8% | 0% | -7% | -33% | 1% | 8% |
Financials of Strides Pharma Science Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 | 92 |
| Reserves | 1,085 | 2,569 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,122 | 2,034 | 2,460 | 3,015 |
| Borrowings + | 892 | 3,542 | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,517 | 1,880 | 1,758 |
| Other Liabilities + | 438 | 1,211 | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,352 | 1,157 | 1,498 | 2,062 |
| Total Liabilities | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,927 |
| Fixed Assets + | 701 | 2,679 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,899 | 2,387 |
| CWIP | 171 | 815 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 | 161 |
| Investments | 630 | 1,341 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 | 291 |
| Other Assets + | 972 | 2,576 | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,470 | 3,414 | 4,088 |
| Total Assets | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,927 |
Financials of Strides Pharma Science Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 | 703 |
| Cash from Investing Activity + | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | -90 | -173 |
| Cash from Financing Activity + | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 | -453 |
| Net Cash Flow | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 | -48 | 76 |
| Free Cash Flow | -157 | -293 | -386 | -212 | -256 | 58 | 188 | -326 | -43 | 672 | 510 | 291 |
| CFO/OP | 61% | 40% | 66% | 61% | 59% | 60% | 60% | 199% | -30% | 128% | 77% | 84% |
Financials of Strides Pharma Science Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 132 | 132 | 113 | 165 | 124 | 122 | 144 | 129 | 107 | 96 | 97 |
| Inventory Days | 135 | 149 | 209 | 146 | 294 | 254 | 329 | 285 | 257 | 235 | 236 | 305 |
| Days Payable | 153 | 188 | 221 | 188 | 299 | 259 | 323 | 260 | 220 | 178 | 190 | 244 |
| Cash Conversion Cycle | 102 | 92 | 120 | 71 | 160 | 119 | 128 | 168 | 165 | 164 | 141 | 157 |
| Working Capital Days | -91 | 6 | -122 | -4 | -70 | -70 | -22 | -28 | -11 | -19 | 24 | 38 |
| ROCE % | 57% | 8% | 11% | 16% | 2% | 5% | 8% | -5% | -0% | 7% | 15% | 19% |